中国药物警戒 ›› 2022, Vol. 19 ›› Issue (7): 712-716.
DOI: 10.19803/j.1672-8629.2022.07.04
• 机制性模型在药物研发和评价中的应用专栏(一) • 上一篇 下一篇
张斗胜, 王晨#, 许明哲*
收稿日期:
2022-02-15
出版日期:
2022-07-15
发布日期:
2022-07-12
通讯作者:
*许明哲,男,博士,主任药师,抗感染药物质量评价研究。E-mail:xumzhe@nifdc.org.cn。#为共同通信作者。
作者简介:
张斗胜,男,博士,主任药师,抗感染药物质量评价研究。
基金资助:
ZHANG Dousheng, WANG Chen#, XU Mingzhe*
Received:
2022-02-15
Online:
2022-07-15
Published:
2022-07-12
摘要: 目的 快速评价注射用左奥硝唑及其主要杂质的潜在神经毒性,为加强临床用药安全性提供参考。方法 利用在线数据库准备建模数据,分别采用人工神经网络和支持向量机算法构建2种不同原理的分类预测模型进行交互快速评价,并采用特征结构域初步探索毒性成因。结果 新建模型中,编号为ANN-3和SVM-2模型预测的假阳性、假阴性结果均小于4.0%,其灵敏度、准确性和稳健性良好;采用新建模型预测评估注射用左奥硝唑及3个主要杂质具有潜在神经毒性,可信度高于90%;特征结构域分析显示结构中羟基取代增加分子极性,是表现出潜在神经毒性的可能原因。结论 左奥硝唑及其主要杂质均表现出潜在神经毒性,需要密切关注注射剂在临床使用中的安全性;也为其他抗生素药物及其杂质的毒性快速识别与评价提供借鉴。
中图分类号:
张斗胜, 王晨, 许明哲. 基于计算模型结合数据库技术快速评价注射用左奥硝唑及其主要杂质的潜在神经毒性[J]. 中国药物警戒, 2022, 19(7): 712-716.
ZHANG Dousheng, WANG Chen, XU Mingzhe. Rapid evaluation of potential neurotoxicity of levornidazole for injection and its main impurities based on computational models and database technology[J]. Chinese Journal of Pharmacovigilance, 2022, 19(7): 712-716.
[1] ZHANG Q, YAN JZ, YAO W, et al.Study on the legal system of drug reevaluation in america, european union, Japan and the Enlightenment to China[J]. China Pharmacy(中国药房), 2019, 30(18): 2449-2454. [2] ZHANG YP, SONG SY, BAO LL.Relationship between mechanism and chemical structure of adverse reactions of fluoroquinolones[J]. China & Foreign Medical Treatment(中外医疗), 2014, 33(7): 130-131. [3] GE YQ, YE XX, LE J, et al.Research progress on toxicity and detection methods of N-nitrosamines genotoxic impurities[J]. Chinese Journal of Pharmaceutical Analysis(药物分析杂志), 2020, 40(1): 83-89. [4] ADAMSON RH, CHABNER BA.The finding of N-nitrosod-imethylamine in common medicines[J]. The Oncologist, 2020, 25(6): 460-462. [5] MICHAEL WC.Understanding and preventing (N-nitrosod-imethylamine) NDMA contamination of medications[J]. The Annals of Pharmacotherapy, 2020, 54(6): 611-614. [6] HU JL, WU T, ZHU DM, et al.In vitro activity of a new antibac-terial agent levornidazole against anaerobic bacteria[J]. Chinese Journal of Infection and Chemotherapy(中国感染与化疗杂志), 2014, 14(2): 18-21. [7] LI WW, YAO MN, ZHAO X, et al.Systematic evaluation of levornidazole in the treatment of anaerobic infection[J]. Chinese Journal of Pharmacoepidemiology(药物流行病学杂志), 2019, 28(3): 13-19. [8] HU J, ZHANG J, CHEN Y, et al.In vitro anaerobic pharma-cokinetic/ pharmacodynamic model to simulate the bactericidal activity of levornidazole against bacteroides fragilis[J]. Clinical Therapeutics, 2017, 39(4): 828-836. [9] ZHAO Y, CHEN Z, HUANG P, et al.Analysis of ornidazole injection in clinical use at post-marketing stage by centralized hospital monitoring system[J]. Current Medical Science, 2019, 39(5): 836-842. [10] SUN JH, WANG ZQ, GU XL, et al.Comparative study of ornidazole enantiomers on the toxic and side effects to central nervous system in mice[J]. Journal of China Pharmaceutical University(中国药科大学学报), 2008, 39(4): 343-347. [11] BAI YT, NAN N, YIN J.Discussion on toxicity prediction of quantitative structure-activity relationship model and its application in impurity prediction[J]. Chinese Pharmaceutical Affairs(中国药事), 2019, 33(10): 1174-1180. [12] LI L, YANG JB.Application progress of physiologically-based pharmacokinetic model in clinicaldevelopment of novel molecular entities[J]. Chinese Journal of Clinical Pharmacology(中国临床药理学杂志), 2017, 33(17): 118-122. [13] PURI M, PATHAK YV, SUTATIYA VK, et al Artificial neural network for drug design, delivery and disposition[M]. Academic press: Salt lake city, USA, 2016: 181-193. [14] SAMUI P, ROY SS, VALENTINA EB.Handbook of neural computation[M]. Academic press: Salt Lake City, USA, 2017: 515-535. [15] GAO YF, FENG JF, ZHU L.Toxicodynamic modeling of zebrafish larvae to metals using stochastic death and individual tolerance models: comparisons of model assumptions, parameter sensitivity and predictive performance[J]. Ecotoxicology, 2017, 26(3): 295-307. [16] AUSTIN JD, HIRSTEIN J, WALEN S.Integrated mathematics interfaced with science[J]. School Science and Mathematics, 1997, 97(1): 45-49. [17] PABLO MC, PARDO-FERNÁNDEZ JC. The youden index in the generalized receiver operating characteristic curve context[J]. The International Journal of Biostatistics, 2019, 15(1): 1-20. [18] JOHN AC.Classical and modern regression with applications[J]. Technometrics, 2012, 29(3): 377-378. [19] KUHN M, LETUNIC I, JENSEN LJ, et al.The SIDER database of drugs and side effects[J]. Nucleic Acids Research, 2016, 44(D1): D1075-D1079. [20] LEI TL, LI YY, SONG YL, et al.ADMET evaluation in drug discovery: 15 accurate prediction of rat oral acute toxicity using relevance vector machine and consensus modeling[J]. Journal of Cheminformatics, 2016, 8(1): 1-19. |
[1] | 孙绮悦, 赵荣华, 郭姗姗, 包蕾, 耿子涵, 李舒冉, 徐英莉, 张敬升, 崔晓兰, 孙静. 羚羊感冒口服液多重药理作用研究[J]. 中国药物警戒, 2024, 21(2): 127-131. |
[2] | 赵荣华, 孙静, 包蕾, 耿子涵, 陶夏莉, 张敬升, 庞博, 徐英莉, 曹姗, 李舒冉, 郭姗姗, 王道涵, 崔晓兰. 基于免疫调节探讨葛根汤颗粒治疗小鼠病毒性肺炎的作用机制[J]. 中国药物警戒, 2024, 21(2): 132-136. |
[3] | 包蕾, 耿子涵, 李舒冉, 冀祖恩, 赵荣华, 孙静, 郭姗姗, 崔晓兰. 瞬时受体电位通道在病毒性肺炎发展过程中的关键作用[J]. 中国药物警戒, 2024, 21(2): 137-140. |
[4] | 贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166. |
[5] | 李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180. |
[6] | 范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184. |
[7] | 张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189. |
[8] | 王珊, 谢波, 刘慧敏, 李志浩. 基于FAERS数据库对塞来昔布不良事件信号的分析[J]. 中国药物警戒, 2024, 21(2): 190-194. |
[9] | 李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198. |
[10] | 徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203. |
[11] | 郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207. |
[12] | 方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210. |
[13] | 李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212. |
[14] | 曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218. |
[15] | 朱盈, 沈璐, 李岚, 吴建民, 高晓洁. 新法规体系下我国牙膏不良反应监测工作分析与思考[J]. 中国药物警戒, 2024, 21(2): 219-222. |
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||